Aroda, M.D., from Brigham and Women's Hospital in Boston, and colleagues randomly assigned adults with type 2 diabetes inadequately controlled with diet and exercise to receive once-weekly subcutaneous cagrilintide 2.4 mg plus semaglutide 2.4 mg, cagrilintide 1.0 mg plus semaglutide 1.0 mg, or placebo for 40 weeks (62, 63, and 64 participants, respectively)
Seek urgent medical attention for severe abdominal pain, chest pain, or significant swelling
In REDEFINE 1 (NEJM 2025, n=3,417, 68 weeks), cagrilintide monotherapy at 2.4 mg produced 11.8% mean body-weight reduction versus 2.3% with placebo
The United States remains the world's largest importer of semaglutide API, predominantly sourcing from Novo Nordisk's vertically integrated manufacturing facilities in Denmark as well as from an expanding roster of CDMO partners
TsienCDavuluriGSinghDAllawyAten HaveGAMThapaliyaSet al
As noted in our earlier blog post, FDA recently clarified its position on compounded glucagon-like peptide-1 (GLP-1) peptides
